Latest Breaking News On - Justine omalley - Page 1 : comparemela.com

Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing

NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative thera.

United statesKlinische einheitJustine omalleyProtara therapeutics incExchange commissionGuggenheim securitiesCompany contactOppenheimer coPre funded warrantsCommon warrantsCommon warrantPre funded warrantAcorn bioventuresBoxer capitalWoodline partnersCatalio capital management

Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition

Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesJustine omalleyJesse sheffermanDennis riedlPalle bekker jeppesenProtara therapeutics incCopenhagen university hospitalCompany contactProtara therapeutics inc nasdaqAmerican society for parenteralHead of the department intestinal failureDrug administrationExchange commissionEuropean society for clinical nutritionCholine chlorideChloride orphan drug designation

Protara Therapeutics Announces Positive Three-Month Data From TARA-002 Clinical Program In NMIBC

Protara Therapeutics Announces Positive Three-Month Data From TARA-002 Clinical Program In NMIBC
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesGautam jayramJustine omalleyJesse sheffermanKlinische einheitTimothy lyonDrug administrationTherapeutics centerClinical programUrology associatesProtara therapeutics incCompany contactUrology residency programExchange commissionChugai pharmaceutical co ltdNon muscle invasive bladder cancer

Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update

Dosing is progressing well in ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expected in 1H24Company init.

United statesJesse sheffermanKlinische einheitJustine omalleyExchange commissionProtara therapeutics incIv choline chloride programChugai pharmaceutical co ltdDrug administrationCompany contactProtara therapeutics inc nasdaqLymphatic malformationsChief executive officerBacillus calmette guOrphan drug designationRare pediatric disease designation

Protara Therapeutics Announces - GuruFocus com

GuruFocus Article or News written by Stock market mentor and the topic is about:

United statesJesse sheffermanJustine omalleyCompany contactWindmil therapeutics incRafael holdings incCore medicalBeyondspring therapeutics incCatalent pharma solutions incCompensation committee of protara board directorsUnipath diagnostics coBiomatrix incProtara therapeutics incPharmaceuticals incProgenics pharmaceuticals incExchange commission